{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:37:04Z","timestamp":1789522624786,"version":"build-2803163510"},"reference-count":25,"publisher":"Innovative Healthcare Institute","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Leiomyosarcoma is a malignant mesenchymal tumor of cells of smooth muscle lineage arising commonly in retroperitoneum, uterus, large veins, and the limbs. The genetics of leiomyosarcomas are complex and there is very limited understanding of common driver mutations. Circulating tumor DNA (ctDNA) offers a rapid and noninvasive method of next-generation sequencing (NGS) that could be used for diagnosis, therapy, and detection of recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ctDNA testing was performed using Guardant360, which detects single nucleotide variants, amplifications, fusions, and specific insertion\/deletion mutations in 73 genes using NGS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 73 patients, 59 were found to have one or more cancer-associated genomic alteration. Forty-five (76%) were female with a median age of 63 (range, 38\u201387) years. All samples were designated metastatic. The most common alterations were detected in Tp53 (65%), BRAF (13%), CCNE (13%), EGFR (12%), PIK3CA (12%), FGFR1 (10%), RB1(10%), KIT (8%), and PDGFRA (8%). Some of the other alterations included RAF1, ERBB2, MET, PTEN TERT, APC, and NOTCH1. Potentially targetable mutations, by Food and Drug Administration\u2013approved or clinical trials, were found in 24 (40%) of the 73 patients. Four patients (5%) were found to have incidental germline TP53 mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NGS of ctDNA allows identification of genomic alterations in plasma from patients with leiomyosarcoma. Unfortunately, there is limited activity of current targeted agents in leiomyosarcomas. These results suggest opportunities to develop therapy against TP53, cell cycle, and kinase signaling pathways. Further validation and prospective evaluation is warranted to investigate the clinical utility of ctDNA for patients with leiomyosarcoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36401\/jipo-20-3","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T16:54:22Z","timestamp":1596732862000},"page":"64-68","source":"Crossref","is-referenced-by-count":13,"title":["Identification of Genetic Alterations by Circulating Tumor DNA in Leiomyosarcoma: A Molecular Analysis of 73 Patients"],"prefix":"10.36401","volume":"3","author":[{"given":"Junaid","family":"Arshad","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Miller School of Medicine, Jackson Memorial Hospital\/University of Miami, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila","family":"Barreto-Coelho","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Internal Medicine, Miller School of Medicine, Jackson Memorial Hospital\/University of Miami, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Jonczak","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Miller School of Medicine, Jackson Memorial Hospital\/University of Miami, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Espejo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Miller School of Medicine, Jackson Memorial Hospital\/University of Miami, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"D'Amato","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Miller School of Medicine, Jackson Memorial Hospital\/University of Miami, Miami, FL, USA"},{"name":"Sylvester Comprehensive Cancer Center, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C.","family":"Trent","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Miller School of Medicine, Jackson Memorial Hospital\/University of Miami, Miami, FL, USA"},{"name":"Sylvester Comprehensive Cancer Center, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"2021072121210616900_i2590-017X-3-2-64-b01","doi-asserted-by":"crossref","unstructured":"Duffaud\n              F,\n            \n            \n              Ray-Coquard\n              I,\n            \n            \n              Salas\n              S,\n            \n            \n              Pautier\n              P.\n            \n          \n          Recent advances in understanding and managing leiomyosarcomas.\n\t\t\t\t\tF1000prime reports.\n\t\t\t\t\t2015;\n\t\t\t\t\t7:\n\t\t\t\t\t55.","DOI":"10.12703\/P7-55"},{"key":"2021072121210616900_i2590-017X-3-2-64-b02","doi-asserted-by":"crossref","unstructured":"Sephien\n              A,\n            \n            \n              Mousa\n              MS,\n            \n            \n              Bui\n              MM,\n            \n            \n              Kedar\n              R,\n            \n            \n              Thomas\n              K.\n            \n          \n          Leiomyosarcoma of the inferior vena cava with hepatic and pulmonary metastases: case report.\n\t\t\t\t\tJ Radiol Case Rep.\n\t\t\t\t\t2019;\n\t\t\t\t\t13:\n\t\t\t\t\t30\u2013\n\t\t\t\t\t40.","DOI":"10.3941\/jrcr.v13i5.3641"},{"key":"2021072121210616900_i2590-017X-3-2-64-b03","doi-asserted-by":"crossref","unstructured":"Setia\n              A,\n            \n            \n              Kanotra\n              S,\n            \n            \n              Aggarwal\n              R,\n            \n            \n              Bhavthankar\n              DP.\n            \n          \n          Epithelioid leiomyosarcoma of uterus.\n\t\t\t\t\tBMJ Case Rep.2012;\n\t\t\t\t\t2012.","DOI":"10.1136\/bcr.11.2011.5144"},{"key":"2021072121210616900_i2590-017X-3-2-64-b04","doi-asserted-by":"crossref","unstructured":"Hashimoto\n              H,\n            \n            \n              Tsuneyoshi\n              M,\n            \n            \n              Enjoji\n              M.\n            \n          \n          Malignant smooth muscle tumors of the retroperitoneum and mesentery: a clinicopathologic analysis of 44 cases.\n\t\t\t\t\tJ Surg Oncol.\n\t\t\t\t\t1985;\n\t\t\t\t\t28:\n\t\t\t\t\t177\u2013\n\t\t\t\t\t186.","DOI":"10.1002\/jso.2930280307"},{"key":"2021072121210616900_i2590-017X-3-2-64-b05","doi-asserted-by":"crossref","unstructured":"Fields\n              JP,\n            \n            \n              Helwig\n              EB.\n            \n          \n          Leiomyosarcoma of the skin and subcutaneous tissue.\n\t\t\t\t\tCancer.\n\t\t\t\t\t1981;\n\t\t\t\t\t47:\n\t\t\t\t\t156\u2013\n\t\t\t\t\t169.","DOI":"10.1002\/1097-0142(19810101)47:1<156::AID-CNCR2820470127>3.0.CO;2-#"},{"key":"2021072121210616900_i2590-017X-3-2-64-b06","doi-asserted-by":"crossref","unstructured":"Casali\n              PG,\n            \n            \n              Blay\n              JY,\n            \n            \n              Bertuzzi\n              A,\n            \n            et al.\n\t\t\t\t\t\n          Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.\n\t\t\t\t\tAnn Oncol.\n\t\t\t\t\t2014;\n\t\t\t\t\t25:\n\t\t\t\t\t102\u2013\n\t\t\t\t\t112.","DOI":"10.1093\/annonc\/mdu254"},{"key":"2021072121210616900_i2590-017X-3-2-64-b07","doi-asserted-by":"crossref","unstructured":"Cuppens\n              T,\n            \n            \n              Moisse\n              M,\n            \n            \n              Depreeuw\n              J,\n            \n            et al.\n\t\t\t\t\t\n          Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.\n\t\t\t\t\tInt J Cancer.\n\t\t\t\t\t2018;\n\t\t\t\t\t142:\n\t\t\t\t\t1230\u2013\n\t\t\t\t\t1243.","DOI":"10.1002\/ijc.31129"},{"key":"2021072121210616900_i2590-017X-3-2-64-b08","doi-asserted-by":"crossref","unstructured":"Arshad\n              J,\n            \n            \n              Roberts\n              A,\n            \n            \n              Nagy\n              RJ,\n            \n            \n              Wilky\n              BA,\n            \n            \n              Trent\n              JC.\n            \n          \n          Utility of circulating tumor DNA (ctDNA) in the management of patients with gastrointestinal stromal tumor (GIST): Analysis of 152 patients.\n\t\t\t\t\tJ Clin Oncol.2018;\n\t\t\t\t\t36(15_suppl):\n\t\t\t\t\t11539\u2013\n\t\t\t\t\t11539.","DOI":"10.1200\/JCO.2018.36.15_suppl.11539"},{"key":"2021072121210616900_i2590-017X-3-2-64-b09","doi-asserted-by":"crossref","unstructured":"Wan\n              JCM,\n            \n            \n              Massie\n              C,\n            \n            \n              Garcia-Corbacho\n              J,\n            \n            et al.\n\t\t\t\t\t\n          Liquid biopsies come of age: towards implementation of circulating tumour DNA.\n\t\t\t\t\tNat Rev Cancer.\n\t\t\t\t\t2017;\n\t\t\t\t\t17:\n\t\t\t\t\t223\u2013\n\t\t\t\t\t238.","DOI":"10.1038\/nrc.2017.7"},{"key":"2021072121210616900_i2590-017X-3-2-64-b10","doi-asserted-by":"crossref","unstructured":"Hemming\n              ML,\n            \n            \n              Klega\n              KS,\n            \n            \n              Rhoades\n              J,\n            \n            et al.\n\t\t\t\t\t\n          Detection of circulating tumor DNA in patients with leiomyosarcoma with progressive disease.\n\t\t\t\t\tJCO Precis Oncol.2019;\n\t\t\t\t\t2019.","DOI":"10.1200\/PO.18.00235"},{"key":"2021072121210616900_i2590-017X-3-2-64-b11","doi-asserted-by":"crossref","unstructured":"Arshad\n              J,\n            \n            \n              Roberts\n              A,\n            \n            \n              Ahmed\n              J,\n            \n            et al.\n\t\t\t\t\t\n          Utility of circulating tumor DNA in the management of patients with GI stromal tumor: analysis of 243 patients.\n\t\t\t\t\tJCO Precis Oncol.2020:\n\t\t\t\t\t66\u2013\n\t\t\t\t\t73.","DOI":"10.1200\/PO.19.00253"},{"key":"2021072121210616900_i2590-017X-3-2-64-b12","doi-asserted-by":"crossref","unstructured":"Penel\n              N,\n            \n            \n              Italiano\n              A,\n            \n            \n              Isambert\n              N,\n            \n            \n              Bompas\n              E,\n            \n            \n              Bousquet\n              G,\n            \n            \n              Duffaud\n              F.\n            \n          \n          Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy.\n\t\t\t\t\tAnn Oncol.\n\t\t\t\t\t2010;\n\t\t\t\t\t21:\n\t\t\t\t\t1361\u2013\n\t\t\t\t\t1365.","DOI":"10.1093\/annonc\/mdp485"},{"key":"2021072121210616900_i2590-017X-3-2-64-b13","doi-asserted-by":"crossref","unstructured":"Sleijfer\n              S,\n            \n            \n              Ouali\n              M,\n            \n            \n              van Glabbeke\n              M,\n            \n            et al.\n\t\t\t\t\t\n          Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).\n\t\t\t\t\tEur J Cancer.\n\t\t\t\t\t2010;\n\t\t\t\t\t46:\n\t\t\t\t\t72\u2013\n\t\t\t\t\t83.","DOI":"10.1016\/j.ejca.2009.09.022"},{"key":"2021072121210616900_i2590-017X-3-2-64-b14","doi-asserted-by":"crossref","unstructured":"Hensley\n              ML,\n            \n            \n              Maki\n              R,\n            \n            \n              Venkatraman\n              E,\n            \n            et al.\n\t\t\t\t\t\n          Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2002;\n\t\t\t\t\t20:\n\t\t\t\t\t2824\u2013\n\t\t\t\t\t2831.","DOI":"10.1200\/JCO.2002.11.050"},{"key":"2021072121210616900_i2590-017X-3-2-64-b15","doi-asserted-by":"crossref","unstructured":"Lee\n              PJ,\n            \n            \n              Yoo\n              NS,\n            \n            \n              Hagemann\n              IS,\n            \n            et al.\n\t\t\t\t\t\n          Spectrum of mutations in leiomyosarcomas identified by clinical targeted next-generation sequencing.\n\t\t\t\t\tExp Mol Pathol.\n\t\t\t\t\t2017;\n\t\t\t\t\t102:\n\t\t\t\t\t156\u2013\n\t\t\t\t\t161.","DOI":"10.1016\/j.yexmp.2017.01.012"},{"key":"2021072121210616900_i2590-017X-3-2-64-b16","doi-asserted-by":"crossref","unstructured":"Batth\n              IS,\n            \n            \n              Mitra\n              A,\n            \n            \n              Manier\n              S,\n            \n            et al.\n\t\t\t\t\t\n          Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.\n\t\t\t\t\tAnn Oncol.\n\t\t\t\t\t2017;\n\t\t\t\t\t28:\n\t\t\t\t\t468\u2013\n\t\t\t\t\t477.","DOI":"10.1093\/annonc\/mdw619"},{"key":"2021072121210616900_i2590-017X-3-2-64-b17","doi-asserted-by":"crossref","unstructured":"Arshad\n              JA,\n            \n            \n              Subhawong\n              T,\n            \n            \n              Trent\n              JC.\n            \n          \n          Progress in determining response to treatment in gastrointestinal stromal tumor.\n\t\t\t\t\tExpert Rev Anticancer Ther.2020;\n\t\t\t\t\t4:\n\t\t\t\t\t279\u2013\n\t\t\t\t\t288.","DOI":"10.1080\/14737140.2020.1745068"},{"key":"2021072121210616900_i2590-017X-3-2-64-b18","doi-asserted-by":"crossref","unstructured":"Chudasama\n              P,\n            \n            \n              Mughal\n              SS,\n            \n            \n              Sanders\n              MA,\n            \n            et al.\n\t\t\t\t\t\n          Integrative genomic and transcriptomic analysis of leiomyosarcoma.\n\t\t\t\t\tNat Commun.\n\t\t\t\t\t2018;\n\t\t\t\t\t9:\n\t\t\t\t\t144.","DOI":"10.1158\/1538-7445.AM2018-4336"},{"key":"2021072121210616900_i2590-017X-3-2-64-b19","doi-asserted-by":"crossref","unstructured":"Azad\n              TD,\n            \n            \n              Chaudhuri\n              AA,\n            \n            \n              Fang\n              P,\n            \n            et al.\n\t\t\t\t\t\n          Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer.\n\t\t\t\t\tGastroenterology.\n\t\t\t\t\t2019;\n\t\t\t\t\t158:\n\t\t\t\t\t494\u2013\n\t\t\t\t\t505.","DOI":"10.1053\/j.gastro.2019.10.039"},{"key":"2021072121210616900_i2590-017X-3-2-64-b20","unstructured":"An\n              Y,\n            \n            \n              Guan\n              Y,\n            \n            \n              Xu\n              Y,\n            \n            et al.\n\t\t\t\t\t\n          The diagnostic and prognostic usage of circulating tumor DNA in operable hepatocellular carcinoma.\n\t\t\t\t\tAm J Transl Res.\n\t\t\t\t\t2019;\n\t\t\t\t\t11:\n\t\t\t\t\t6462\u2013\n\t\t\t\t\t6474."},{"key":"2021072121210616900_i2590-017X-3-2-64-b21","doi-asserted-by":"crossref","unstructured":"El-Rifai\n              W,\n            \n            \n              Sarlomo-Rikala\n              M,\n            \n            \n              Knuutila\n              S,\n            \n            \n              Miettinen\n              M.\n            \n          \n          DNA copy number changes in development and progression in leiomyosarcomas of soft tissues.\n\t\t\t\t\tAm J Pathol.\n\t\t\t\t\t1998;\n\t\t\t\t\t153:\n\t\t\t\t\t985\u2013\n\t\t\t\t\t990.","DOI":"10.1016\/S0002-9440(10)65640-4"},{"key":"2021072121210616900_i2590-017X-3-2-64-b22","doi-asserted-by":"crossref","unstructured":"Svarvar\n              C,\n            \n            \n              Larramendy\n              ML,\n            \n            \n              Blomqvist\n              C,\n            \n            et al.\n\t\t\t\t\t\n          Do DNA copy number changes differentiate uterine from non-uterine leiomyosarcomas and predict metastasis?\n          \n            Mod Pathol\n          .\n\t\t\t\t\t2006;\n\t\t\t\t\t19:\n\t\t\t\t\t1068\u2013\n\t\t\t\t\t1082.","DOI":"10.1038\/modpathol.3800617"},{"key":"2021072121210616900_i2590-017X-3-2-64-b23","doi-asserted-by":"crossref","unstructured":"Kogan\n              S,\n            \n            \n              Carpizo\n              D.\n            \n          \n          Pharmacological targeting of mutant p53.\n\t\t\t\t\tTransl Cancer Res.\n\t\t\t\t\t2016;\n\t\t\t\t\t5:\n\t\t\t\t\t698\u2013\n\t\t\t\t\t706.","DOI":"10.21037\/tcr.2016.11.74"},{"key":"2021072121210616900_i2590-017X-3-2-64-b24","doi-asserted-by":"crossref","unstructured":"Shulman\n              DS,\n            \n            \n              Klega\n              K,\n            \n            \n              Imamovic-Tuco\n              A,\n            \n            et al.\n\t\t\t\t\t\n          Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.\n\t\t\t\t\tBr J Cancer.\n\t\t\t\t\t2018;\n\t\t\t\t\t119:\n\t\t\t\t\t615\u2013\n\t\t\t\t\t621.","DOI":"10.1038\/s41416-018-0212-9"},{"key":"2021072121210616900_i2590-017X-3-2-64-b25","doi-asserted-by":"crossref","unstructured":"Przybyl\n              J,\n            \n            \n              Chabon\n              JJ,\n            \n            \n              Spans\n              L,\n            \n            et al.\n\t\t\t\t\t\n          Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma.\n\t\t\t\t\tClin Cancer Res.\n\t\t\t\t\t2018;\n\t\t\t\t\t24:\n\t\t\t\t\t2688\u2013\n\t\t\t\t\t2699.","DOI":"10.1158\/1078-0432.CCR-17-3704"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/3\/2\/64\/2870954\/i2590-017x-3-2-64.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/3\/2\/64\/2870954\/i2590-017x-3-2-64.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:12Z","timestamp":1765475292000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/3\/2\/article-p64.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,6,5]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-20-3","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}